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The prognostic and predictive role of biomarkers in colorectal cancer is still being defined. 
The aim of this study was to determine the prognostic value of BRAF mutation alone and in 
combination with microsatellite instability (MSI), and to determine the interaction between 
BRAF mutation and MSI status in determining survival benefit after adjuvant 5-FU (5-
fluorouracil) based chemotherapy in stage III colon cancer. 
Methods 
We performed a retrospective cohort study including all curatively resected stage III colon 
cancer cases over a 33-year period. A clinicopathologic database was collated (adjuvant 
chemotherapy, age, gender, obstruction, perforation, tumour location, grade, mucin, nodal 
stage, extramural vascular and perineural invasion). BRAF (V600E) mutation testing was 
performed and MSI status established by immunohistochemistry for mismatch repair 
proteins and molecular testing for National Cancer Institute (NCI) panel markers. Patients 
were categorised into four groups for comparison: MSS and BRAF-ve (termed “traditional”), 
MSI and BRAF-ve (termed “presumed Lynch”), MSI and BRAF+ve (termed “sporadic MSI”) 
and MSS and BRAF+ve (termed “other BRAF”). The primary endpoint was cancer specific 
survival. Interaction testing was conducted to determine whether there was differential 
benefit from chemotherapy between groups. 
Results 
A total of 686 unselected cases met our inclusion criteria and had tissue available, of which 
15.7% had BRAF mutation and 13.8% had MSI. In the adjusted analysis, neither BRAF 
mutation nor MSI mutation were independently prognostic (HR 1.78, 95% CI 0.89-1.79, P = 
0.18, and HR 0.49, 95% CI 0.75-1.83, P = 0.48, respectively). On univariate analysis, 
survival of patients with presumed Lynch cancers was similar to those with traditional 
cancers (5-year survival, 62 and 61%, respectively), and while there was no difference in 
cancer specific survival between sporadic MSI and other BRAF, these tumours had poorer 
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outcome when compared to traditional or presumed Lynch cancers. Adjusted analysis of the 
four groups, however, showed that none of the subgroups were independently prognostic. 
Thirty-nine percent received chemotherapy. Overall, adjuvant chemotherapy produced a 
cancer specific survival benefit (chemotherapy: HR 0.66, 95% CI 0.49-0.88, P < 0.01). On 
adjusted analysis, neither BRAF nor MSI status were individually predictive of survival 
benefit. On adjusted analysis specifically of the chemotherapy effect in each subgroup, only 
patients in the presumed Lynch group (HR 0.260, 95% CI 0.09-0.80, P < 0.01) and other 
BRAF groups (HR 0.45, 95% CI 0.23-0.87, P 0.01) had a significant survival benefit from 
chemotherapy. On interaction testing of subgroups, adjusting for all the clinicopathological 
parameters, patients in the presumed Lynch group (HR 0.28, 95% CI 0.10-0.75, P < 0.01) 
gained a differentially greater benefit from chemotherapy than other groups. 
Conclusions 
BRAF mutated cancers demonstrated a trend towards poorer outcomes, however, after 
adjusting for clinicopathological factors, MSI and chemotherapy, BRAF mutation was not 
found to be an independent prognostic biomarker in stage III colon cancer, even when 
combined with MSI. In this historical cohort, MSI testing was predictive of response to 
adjuvant chemotherapy in stage III colon cancer, but only when results are interpreted in 
combination with BRAF. This supports the role of routine testing for these biomarkers. 
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The development of colorectal cancer (CRC) is a multi-step process, with a complex 
interplay of factors that are still being elucidated. Molecular mechanisms are important but 
so far there has been limited success in using biomarkers to stratify patients with colorectal 
cancer for treatment, targeted therapy and prognostication. Of the various major pathways in 
CRC, the serrated pathway of colorectal cancer is the most recently described and thus 
least well understood. In this review of the literature, we evaluate the serrated pathway in 
colorectal cancer and explore further its molecular basis. 
Introduction 
Despite advances in management of colorectal cancer (CRC) over the last couple of 
decades there is significant cancer-related mortality associated with this disease (1). 
Historically, CRC has been managed as a single entity (2), but it is now recognised that 
multiple distinct pathways exist in colorectal cancer (3). There is wide variation in the 
incidence of colorectal cancer by geographical location and gender (1, 2), possible reflecting 
significant heterogeneity in pathogenesis of these cancers. Despite recognising 
morphological subtypes of CRC, such as mucinous carcinoma (4) for decades, it has only 
become apparent recently that CRC is not a single disease, but rather a heterogenous 
disorder including multiple pathways with diverse molecular backgrounds and 
clinicopathological manifestations. About a third of colorectal cancers are now thought to 
develop through an alternative pathway to the adenoma to carcinoma sequence as 
described by Vogelstein et al. (3, 5). It is important that with the growing knowledge of 
colorectal cancer tumorigenesis, due attention is given to new findings related to histological 
assessment, and molecular characterisation, prognostic and predictive information, to 
improve the cancer-related mortality seen with this disease. 
Genetic instability in different pathways 
Historically, the progression of colorectal cancer was thought to follow the adenoma to 
carcinoma sequence, with driver APC (adenomatous polyposis coli) activation in adenoma, 
with additional KRAS mutation and p53 inactivation in carcinoma. This pathway, also 
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described as the chromosomal instability (CIN) pathway or traditional adenoma to carcinoma 
sequence is well established in colorectal tumorigenesis (5). However, the genetic and 
epigenetic alterations seen in colorectal cancer tumorigenesis are complex and difficult to 
understand. The CIN pathway only accounts for about 60-70% of CRC. The notion that an 
independent alternative pathway exists in sporadic CRC was slow to develop, and a second 
model of genetic instability was only accepted when adenomas in Lynch syndrome (a type of 
hereditary colorectal cancer) patient were found to accumulate a number of mutations which 
specifically target repetitive sequences of DNA (6). This form of genetic instability is caused 
by inactivation of the DNA mismatch repair (MMR) system and microsatellite instability (MSI) 
is the biomarker (7-9). The existence of two different pathways (CIN-traditional and MSI-
alternative) led to further research to understand the distinct pathological and molecular 
characteristics of these pathways, and to characterise their precursor lesions and clinical 
manifestations. 
Alternative pathway or serrated cancers 
Jass and Smith first described pathological characteristics of alternative pathway cancers in 
1992 (10). These alternative pathway cancers may have epithelial serrations, eosinophilic 
and abundant cytoplasm with vesicular nuclei, chromatin condensation and lack of necrosis, 
mucin production, and presence of cell balls and rods (10, 11). Given their distinct 
morphological characteristics they were described as serrated cancers (SC). However, only 
a small number of alternative pathway cancers show these characteristic histopathological 
features, and histologically distinguishing serrated cancers from common cancers (arising 
from the CIN pathway) is difficult (11-13). Mäkinen et al. first described the relationship 
between a distinctive polyp that histologically showed epithelial serration (serrated 
architecture) and serrated cancer (11). These polyps were later defined as serrated polyps 
or serrated adenomas (14), and due to their serrated architecture were thought to be 
precursor lesions to alternative pathway cancers. The presence of serrated polyps in the 
periphery of infiltrating carcinoma is another very important histological finding that helps 
distinguish serrated cancers (12). However, histological distinction of these cancers can still 
be quite difficult, and it is hypothesised that this may be due to loss of histological 
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characteristics as the lesion progresses. Therefore, identification of these serrated cancers 
must rely on molecular characteristics. 
Molecular characteristics of serrated cancers 
Research over the last two decades has improved recognition of serrated lesions, both 
endoscopically and on pathology (15). Despite a continually growing understanding of 
underlying serrated cancer tumorigenesis (3, 15), the molecular profile of these tumours is 
heterogenous and less well characterised. The mitogen-activated protein kinase (MAPK) 
cascade is implicated to serrated cancer tumorigenesis due to high frequency of both BRAF 
and KRAS in serrated adenomas (16), and serrated cancers (9). Both BRAF and KRAS 
encode kinases within the MAPK cascade that mediate cellular signalling for cell 
proliferation, apoptosis and differentiation (17). Activation of either of these two mutations 
leads to activation of the MAPK pathway. Interestingly, despite being part of same pathway, 
BRAF and KRAS mutations are mutually exclusive (9, 18), suggesting that tumours derived 
from these mutations may have different biology and natural history. It is also unclear which 
of the two mutations, if either, is the dominant oncogene driving tumour proliferation in 
serrated cancers. Stefanius et al. (9) studied the incidence of BRAF and KRAS mutations in 
non-serrated (CIN pathway) and serrated cancers, histologically confirmed by two 
independent pathologists. This study found that BRAF mutation was exclusively found in 
serrated cancers and is a likely diagnostic mutation for serrated cancers. Interestingly, KRAS 
mutation was found in both serrated and non-serrated cancers, suggesting KRAS mutation 
may be part of the tumorigenic process in these cancers, thus challenging the long-held 
Vogelstein theory. Precursor serrated lesions rarely demonstrate MSI (16, 19-23), and only 
about 20% of serrated cancers are MSI (9). Therefore, high frequency of BRAF and KRAS 
mutations, and the relatively low frequency of MSI in precursor serrated lesions, suggests 
that the MAPK cascade is central in initiating serrated cancer tumorigenesis. BRAF and 
KRAS are early driver mutations of this pathway, initiating tumorigenesis while mismatch 
repair dysfunction is likely a late event. This perhaps clarifies early and late events in 
serrated cancer, but the progression of tumorigenesis in these cancers is unclear. 
 15
It is hypothesised that epigenetic silencing (by DNA hypermethylation) of key genes may 
explain progression from dysplasia (in precursor serrated lesion) to cancer in alternative 
pathway tumours (24), but this remains to be validated. Issa et al. first introduced the 
concept of epigenetic silencing of CpG islands and defined it as the CpG island methylator 
phenotype (CIMP) (25). CpG islands are located in the promotor region of multiple genes 
(70%) and in normal cells these promotor CpG island loci are protected and scarcely 
methylated (26). However, aberrant hypermethylation of CpG islands leads to silencing of 
key genes such as MLH1, MGMT and development of either microsatellite stable or unstable 
cancer depending on which genes are silenced (25, 27). CIMP is thought to be an acquired  
change, mainly because of a gradual increase of CIMP cancer incidence with advancing age 
(28, 29). This suggests that the ageing right colon becomes prone to hypermethylation, 
possibly secondary to potential causes such as smoking, obesity, diet and sedentary 
lifestyle. However, the exact cause of CIMP is not yet known (30), and there is still 
controversy regarding the clinical utility of this category (30). 
BRAF mutation is common in sporadic MSI CRC and CIMP, but not in Lynch syndrome (18, 
25, 30). This led researchers to speculate that progression of BRAF mutated (26, 31-33) 
sporadic MSI tumours could be due to silencing of key genes (MLH1, MGMT) by 
hypermethylation (30), and that BRAF mutation may contribute to the development of CIMP 
(34, 35). The hypothesis is that BRAF mutation activates the MAPK cascade, predisposing 
to promoter hypermethylation (34-36). 
This hypothesis is a plausible explanation of serrated pathway tumorigenesis, but it remains 
to be validated. However, Carragher et al. demonstrated that unidentified factors apart from 
BRAF mutation are required to generate epigenetic changes (34). Similarly, Hinoue et al. 
found that transfection of BRAF mutant to colonic tumour lines did not lead to aberrant DNA 
hypermethylation (35). There are no data on the effect of KRAS mutation on CIMP. 
Therefore, the exact cause of CIMP and progression of serrated polyps to serrated cancer 
remain unknown. 
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Precursor lesions to serrated cancer 
Historically, hyperplastic polyps (HP) were considered benign with no malignant potential. In 
1996, Torlakovic et al. demonstrated histological differences between adenomas and 
hyperplastic polyps (37). Subsequently atypical histological features were identified in HPs, 
and CRC arising in HPs (38). These findings suggested that another precursor lesion may 
give rise to CRC separate from the Vogelstein pathway. HPs with atypical features and 
dysplasia (epithelial serration) were labelled as sessile serrated adenoma (SSA) or serrated 
adenoma (SA) (37). However, which HPs led to SSA was debated, and this led pathologists 
to look at histological similarities between of the histology of HPs and molecular 
characteristics of these lesions. Based on histological features (15), HPs can be divided into 
two main subtypes: microvesicular hyperplastic polyps (MVHP) and goblet cell hyperplastic 
polyps (GCHP) (16, 20). Based on histological and molecular similarities between certain 
HPs, SSA and serrated cancer (cancer with serrated architecture, when present), it does 
appear that they are a continuum from polyp to cancer (15). 
The high incidence of driver mutations such as BRAF and KRAS in HPs add weight to their 
being precursor lesions to serrated pathway cancers (12, 16, 20). KRAS mutations were 
found to be more common in GCHP (20). Whereas, BRAF mutation was seen more 
commonly in MVHPs (16), again reflecting the mutually exclusive nature of these mutations 
within the MAPK pathway, and demonstrating the multiple pathways leading to cancers 
within the serrated pathway. Interestingly, these precursor HPs have rarely demonstrated a 
high level of MSI (16, 19-23). 
Molecular classification of colorectal cancer 
The main aim of classifying CRC and studying prognostic and predictive value of different 
biomarkers is to aid clinical practice and help in treatment decision making and genetic 
counselling. Based on molecular differences in CRC, Jass et al proposed a molecular 
classification according to clinicopathological characteristics (3). 
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Group A: MSI (BRAF mutated/KRAS wild type/CIMP+ve) 
Group A accounts for 10-12% (3) of CRCs. Tumours in this group have propensity to occur 
in older women, are found more often in the proximal colon, present at high tumour (T-stage) 
stage and are considered common tumours derived from the serrated pathway (3, 39). 
Histologically, this group of cancers may show features characteristic of serrated cancers (8) 
(epithelial serrations, eosinophilic and abundant cytoplasm, chromatin condensation and 
lack of necrosis and mucin production) and the most common precursor lesions seen are 
MVHPs (16, 20) or SSA (39). Molecularly, this group of cancers have BRAF mutation and 
show aberrant DNA hypermethylation leading to silencing of key genes, such as MLH1, 
which leads to development of dysplasia and microsatellite instability (3, 30, 39). These 
tumours are usually higher grade but have a favourable prognosis when compared with 
stage-matched controls (40-43). 
Group B: MSS (BRAF mutated/KRAS wild type/CIMP+ve) 
Group B accounts for 8% (3) of CRCs and similarly have a predilection for proximal colon 
(3), are often poorly differentiated, exhibit mucinous histology (44), contain signet ring cells 
(45), have a higher rate of lymphatic, vascular and perineural invasion and lymph node 
metastases compared than other CRCs (44). Similar to group A, the histology of this group 
of cancers may reveal features characteristic for SC (3). The most common precursor lesion 
for this group of cancer is SSA (39). Molecularly, this group of tumours also has BRAF 
mutation but CIMP in this group leads to hypermethylation of either MGMT or P16, which 
then leads to dysplasia, but not MLH1, so they do not show microsatellite instability (3, 39). 
In most series, they have a relatively poorer prognosis (44, 46, 47). 
Jass suggested that group B might be a fusion pathway with overlapping features from the 
two major colorectal cancer pathways, conventional (CIN) and serrated. In these pathways, 
MGMT serves as a crossover point; fusion of these two pathways may generate lesions with 
enhanced aggressiveness (48). Recently, Bond et al. (49) found significantly increased 
levels of overall CIN with advanced stages of presentation, higher number of lymph node 
involvement and metastases in BRAF mutant/MSS cancer, leading to a hypothesis that CIN 
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may contribute to progression of this type of cancer. Based on this evidence (49), it can be 
hypothesised that MAPK initiates tumorigenesis in this group of CRC and further 
progression is via CIN. The compounding effects of these two different pathways could 
contribute to the aggressive phenotype and unfavourable outcomes observed in this group 
of patients. 
Group C: MSS (serrated KRAS mutated/BRAF wild type/CIMP+ve) 
Group C accounts for 20% (3) of CRCs. The most common precursor lesion is the serrated 
adenoma (31) Tumours in this group have not been clearly defined due to current difficulty in 
differentiating KRAS mutated cancers in the serrated pathway from KRAS mutated CIN 
cancers (3), Hence, there are limited specific clinicopathological data relating to these 
tumours (27, 50). 
Group D: MSS (CIN; KRAS mutated/BRAF wild type/CIMP-ve) 
Group D accounts for the majority of CRCs at 57% (3). They have been well described by 
the adenoma to carcinoma sequence (3, 5). Most are sporadic but this group includes 
cancers associated with FAP (familial adenomatous polyposis) (3). 
Group E: MSI (BRAF wild type/CIMP-ve) 
Group E accounts for 3-5% of CRCs (3) and are Lynch syndrome tumours. They are due to 
germline mutation of DNA mismatch repair gene and demonstrate MSI (3). Tumours in this 
group are MSI-H but do not have BRAF V600E mutation (3). BRAF mutation is a surrogate 
marker for hypermethylation (CIMP). The presence of BRAF mutation virtually excludes 
Lynch syndrome (51, 52). Histology of this group of cancers may reveal features 
characteristic for SC (8), tend to affect a younger population (51, 53) and have good 
prognosis when compared with stage-matched controls (54). 
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Figure 1 – Colorectal tumorigenesis and subgroups  
!  
This classification system of Jass et al. has changed the understanding and perspectives of 
the serrated cancer pathway. However, there are still gaps in knowledge in the tumorigenic 
process in SC. The main cause of epigenetic silencing of key genes remain unclear even 
though the BRAF theory is commonly accepted. There are no molecular markers with which 
to identify different KRAS mutated cancers, and future studies to completely profile the 
genome with may help understand these missing links. 
Prognostic value of individual molecular mutations in serrated cancer 
Given the varying molecular pathways leading to CRC (3), it could be predicted that 
prognoses of patients will vary according to presence or absence of different molecular 
mutations. Thus, knowing the molecular characteristics of a patient’s tumour aids 
personalised cancer treatment, increasing the ability to prognosticate accurately and to 
guide treatment effectively. 
The individual markers of the serrated pathway (BRAF, KRAS and MSI) have been studied 
for their prognostic value but this is yet to fully established for stage III CRC. Most studies 
have shown that patients with early stage MSI CRC have a better 5-year survival compared 




analysis evaluating MSI status reported a more favourable prognosis across all stages of 
CRC (43). However, more recent studies have found no difference in prognosis based on 
MSI status alone especially in stage III disease (55-57). 
Several studies have shown that patients with BRAF mutated cancer do poorly (58-60). The 
presence of BRAF mutation in MSI colorectal cancer distinguishes sporadic MSI cases from 
Lynch syndrome (52, 61). However, few studies have examined the prognostic value of 
BRAF in combination with MSI. Interestingly, even though there is high incidence of BRAF 
mutation in sporadic MSI cancer (range 13-78%) (47, 62, 63) in comparison to MSS tumour 
(<10%) (47, 62, 63), the poor prognosis of BRAF mutation in MSS CRCs does not appear to 
have the same effect in MSI CRCs (64). The molecular mechanisms underlying this disparity 
in prognosis are currently unknown. 
Two studies that evaluated the prognostic role of KRAS mutations found no prognostic 
impact in non-metastatic CRCs patients (65, 66). However, in a recent Korean study KRAS 
mutation was found to have an adverse prognostic impact on stage II or III CRC patients 
(67). However, these studies included all KRAS mutated cancers. It is postulated that KRAS 
mutation occurs in the serrated pathway as well as in the CIN pathway, and no one has 
attempted to differentiate them prognostically due to difficulty in differentiating KRAS 
mutated cancers formed via the serrated pathway from KRAS mutated cancers formed via 
the CIN pathway. 
According to the Jass classification, molecular combination may signify different pathways 
and, therefore, BRAF, KRAS and MSI mutations may provide greater prognostic information 
when assessed in combination. However, it is not known if this information will have impact 
on routine clinical and surgical practice. 
Predictive role of individual molecular mutations in serrated cancer 
While 5-FU based adjuvant chemotherapy has been shown to reduce the risk of recurrence 
(68, 69) in CRC, it only leads to 8-10% improvement in overall 5-year survival in stage III 
CRC (70, 71), and even less in stage II CRC (55). Given cancer biology influences disease 
progression, it may also influence response to chemotherapy (3, 72, 73). This gives rise to 
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the question of whether individualised therapy for the patient based on a better 
understanding of CRC tumour biology may avoid the toxicity, cost and inconvenience 
associated with over treatment of patients who may get no additional benefit from adjuvant 
chemotherapy. 
While most recent research has tried to identify factors other than stage to predict who will 
gain benefit, a consistent molecular marker has not been identified. There is equivocal 
evidence in the literature regarding the predictive value of MSI. Evidence from earlier in vitro 
studies showed that inactivation of the MMR system can result in resistance, or rather, 
tolerance to 5-FU treatment (74-76). However, the mechanism underlying this effect is 
unclear. Some early non-randomised retrospective studies actually showed greater 
chemotherapy benefit in MSI-H cases (40, 41, 77) but may have only highlighted the better 
prognosis seen in MSI-H cases (78, 79). In 2003, Ribic et al. used retrospectively analysed 
data from five randomised controlled trials (RCTs) and found a trend towards MSI showing 
less benefit from 5-FU based chemotherapy (42). This led to a change in practice, with 
tumours showing MSI not always offered adjuvant 5-FU chemotherapy. Subsequently in 
2010, Sargent et al. pooled data from the Ribic et al. study with the addition of 457 further 
cases and found significant results (42, 80). In addition, the Sargent group found that stage 
II MMR deficient (MSI) cases had a decreased overall survival in the chemotherapy group 
relative to the MSS group, however, no detrimental effect was observed in stage III cases 
(80). In contrast to the above two studies, reanalysis of data from two large RCT and other 
work found MSI status does not affect chemotherapy responsiveness (57, 72, 81). These 
highly heterogeneous studies with conflicting results have contributed to confusion about 
MSI status. Importantly, the use of MSI as a single molecular marker does not independently 
explain the heterogeneity seen in SC. 
Furthermore, cancers associated with sporadic MSI and MSI associated with Lynch 
syndrome behave differently. Lynch syndrome patients usually have early-onset colon 
cancer (51, 53). This has been suggested by recent work, with Sinicrope et al. reanalysing 
data from previous RCTs with patients from the Ribic et al. and Sargent et al. studies (57, 
72, 81, 82). MSI cancers were found to benefit from chemotherapy, though, the benefit was 
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limited to the presumed germline cases (82). However, Sinicrope et al. did not have 
molecular confirmation of Lynch syndrome in all patients. BRAF V600E was confirmed in 
some, while others were only assumed to be Lynch if there was MLH1 loss in patients under 
55 years at diagnosis. Based on these findings, it can be hypothesised that BRAF mutation 
may impact on the responsiveness of MSI-H sporadic cancer to chemotherapy. This 
however, requires further validation. 
Only a few studies have examined the impact of BRAF mutation alone on the efficacy of 
adjuvant chemotherapy for CRC (72, 73, 83). Hutchins et al. assessed BRAF mutation in 
predicting the recurrence and benefit from chemotherapy in stage II CRC from the QUASAR 
trial (n = 1584). In this trial patients were randomly assigned to chemotherapy (5-FU and 
folinic acid) and no chemotherapy groups. BRAF mutation was found not to be predictive of 
chemotherapy benefit (recurrence used as an outcome measure) (72). However, this study 
had limited statistical power due to fewer recurrences in BRAF mutated cancers (risk ratio = 
0.86, 95% CI 0.57-1.22, P = 0.36) (72). 
Ogino et al. found no significant trend for better survival with combinations of fluorouracil or 
leucovorin with irinotecan in stage III CRC patients with BRAF V600E mutation, compared to 
patients without BRAF mutation (HR = 0.52, 95% CI 0.25-1.10) (83). 
The MRC FOCUS trial examined the impact of BRAF mutation on overall survival (OS) and 
progression-free survival (PFS) with use of 5-FU, either with oxaliplatin or irinotecan in 
advanced colorectal cancer. This study found that BRAF mutation status does not affect the 
impact of irinotecan or oxaliplatin on PFS or OS and concluded that BRAF mutation is not a 
predictive biomarker of differential benefit (73). However, the low frequency of BRAF 
mutation this study reduced its power to detect or exclude any BRAF specific effect. Given 
the lack of evidence for an adjuvant predictive role of BRAF mutation in CRC, further studies 
are required to establish its role as a predictive biomarker. 
KRAS mutation predicts resistance to anti-epidermal growth factor receptor (EGFR) therapy 
in the metastatic setting (84, 85). The role of anti-EGFR therapy in adjuvant setting has not 
been established due to high toxicity and lack of benefit reported in various studies (65, 66). 
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The literature on the predictive role of KRAS mutation in non-metastatic CRC to 5-FU is 
conflicting (86, 87). Results from an CALGB 89803 adjuvant chemotherapy trial (5-
fluorouracil or leucovorin with or without irinotecan) found that the effect of adjuvant 
chemotherapy did not differ according to KRAS mutation status, adjusting for all 
clinicopathological parameters and chemotherapy (65). In contrast to CALGB study, a single 
centre retrospective study, assessing the predictive role of KRAS mutation to adjuvant 5-FU 
chemotherapy, found adjuvant chemotherapy improved 3-year disease-free survival only 
among patients with KRAS mutant tumours (with and without chemotherapy, 78.0 and 
69.2%, respectively) (88). These results remained significant even on multivariate analysis 
(HR 0.454, 95% CI 0.229-0.901, P = 0.024) (88). There are no studies, however, that 
attempted to differentiate KRAS mutated tumours based on its pathway of origin (CIN 
pathway or from KRAS serrated pathway), and as previously stated differentiating these 
groups is difficult. 
Conclusions 
Most colorectal cancer biomarkers still have limited utility in guiding adjuvant therapy. Thus 
far, only tumour stage and associated validated pathological prognostic parameters have 
been shown to be useful in guiding treatment strategy. It is still hoped that further research, 
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Purpose: The prognostic value of biomarkers in colorectal cancer is still being defined. This 
study aimed to determine the prognostic value of BRAF mutation alone, and in combination 
with microsatellite instability (MSI), in stage III colon cancer. 
Methods: Curatively resected stage III colon cancers were studied from a 33-year period. 
Clinicopathological data was collated (adjuvant chemotherapy, age, gender, obstruction, 
perforation, tumour location, grade, presence of mucin, nodal stage, extramural vascular and 
perineural invasion). MSI status was established and molecular testing for BRAF (V600E) 
was performed. Four mutation categories were examined: MSS and BRAF-ve (termed 
“traditional”), MSI and BRAF-ve (termed “presumed Lynch”), MSI and BRAF+ve (termed 
“sporadic MSI”) and MSS and BRAF+ve (termed “other BRAF”). The endpoint was cancer 
specific survival. 
Results: A total of 686 unselected cases met our inclusion criteria, of which 15.7% had a 
BRAF mutation and 13.8% showed MSI. On adjusted analysis, neither BRAF mutation nor 
MSI mutation were independently prognostic. On univariate analysis, survival in presumed 
Lynch cancers was similar to traditional cancers (5-year survival, 62 and 61%, respectively). 
While there was no difference in cancer specific survival between sporadic MSI and other 
BRAF, both these tumour groups had poorer outcome when compared to traditional or 
presumed Lynch cancers. Adjusted analysis of the four groups, however, showed that none 
of the subgroups were independently prognostic. 
Conclusions: BRAF mutated cancers demonstrated a trend towards poorer outcomes, 
however, when adjusted for clinicopathological factors and chemotherapy, BRAF mutation 
was not found to be an independent prognostic biomarker in stage III colon cancer, even 
when combined with MSI. 
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Introduction 
The future of personalised oncology relies on accurate prognostication of colorectal cancer 
(CRC). Understanding of colorectal tumorigenesis has evolved over the last two decades 
and CRC is now considered to be a multi-pathway disease. The chromosomal instability 
(CIN) pathway, adenoma to carcinoma sequence, leads to aneuploidy, oncogene activation 
and loss of tumour suppressor genes. While most CRCs exhibit CIN (60-70%), about 
15-30% of cancers develop via an alternative serrated pathway of tumorigenesis. These 
cancers are formed via activation of the mitogen-activated protein kinase pathway (MAPK), 
and exhibit either BRAF or KRAS mutation (part of the RAS-RAF-MAP2K signalling 
pathway), a major driver of serrated cancer tumorigenesis. They may also demonstrate DNA 
CpG island hypermethylation (CIMP), with or without microsatellite instability (MSI) (3). It 
would seem that the CIN and serrated pathways are mutually exclusive, although the 
molecular biology of tumours involving the serrated pathway is very heterogeneous, and not 
yet completely characterised (3). 
Most studies have shown that patients with early stage MSI CRC have a better 5-year 
survival compared to microsatellite stable (MSS) cases, with about half the risk of death (55, 
56). Studies have also shown that patients with BRAF mutated cancer do poorly (59, 60). 
The presence of BRAF mutation in MSI colorectal cancer distinguishes sporadic MSI cases 
from Lynch syndrome, however, whether presence or absence of MSI has a prognostic 
impact on BRAF mutated cancers is yet to be established. The aim of this study was to 
determine prognostic value of both the BRAF mutation and the combination of BRAF/MSI in 
curatively resected stage III colon cancer. 
Methods 
This was a retrospective cohort study, comparing survival in patients with curatively resected 
stage III colon adenocarcinoma, looking for a compounding effect from clinical and 
pathological parameters and mutational status (BRAF, MSI or combination of BRAF plus 
MSI). All identifiable patients treated for colonic adenocarcinoma within the Central and 
Northern Adelaide Local Health Network over a 33-year period were screened for inclusion. 
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Patient data were derived and collated from regional and national cancer registries and 
pathology databases. Pathology reports were reviewed, and pathology reassessed from 
slides archived from the earlier cases to meet current reporting protocols. Patients were 
excluded if death occurred perioperatively, if surgical margin was positive for tumour (R1 
resection), or if they had metachronous colorectal cancer within 5 years. Synchronous 
cancers were included. Appropriate ethics approval was obtained from the Royal Adelaide 
Hospital Human Research Ethics Committees (approval number 140108). 
A collated clinicopathological database was created including data regarding patient age, 
gender, and whether they received adjuvant chemotherapy. Tumour characteristics, 
including obstruction (defined as proximal dilatation on the pathology report), perforation 
(defined as occurring through the tumour on the pathology report) and tumour location, were 
recorded. Proximal cancers were defined as cancers from the caecum to the splenic flexure 
inclusive and distal cancers defined as tumours distal to the splenic flexure. Rectal cancers 
were excluded. Histologic features including grade (well and moderately differentiated 
tumours were grouped together and poor differentiation recorded separately), mucinous 
component (positive if mucin present), T-stage (T1 and T2 grouped together, and similarly 
T3 and T4), nodal stage (N1 and N2), extramural vascular and perineural invasion were 
recorded. Death data were sourced from the South Australian State Cancer Registry, 
hospital cancer registry, patient case notes and by checking patients’ final clinic visits. 
Hospital and state cancer registries are regularly updated with information from national 
databases to capture interstate deaths. Case notes were reviewed if required to capture 
missing data. 
MSI status was established on formalin fixed paraffin embedded (FFPE) archived specimens 
from 1980 to 2002 by determining instability in mononucleotides sequences BAT40 and 
BAT26, the latter being highly specific for MSI high. The complete National Cancer Institute 
(NCI) panel was run on equivocal cases with MSI defined by instability in two or more 
markers. From 2002 onwards, MSI status has routinely been established on all through IHC 
expression of DNA mismatch repair (MMR) proteins and by molecular testing for the full NCI 
panel of markers (BAT25, BAT26, BAT40, D2S123, D10S197, D17S579, D18S34, D5S346 
 29
and D17S250). Tumours showing instability at two or more loci were defined as 
microsatellite unstable (MSI). Tumours showing no abnormal loci or instability at one locus 
were classified as microsatellite stable (MSS). 
Mutation testing was performed on DNA isolated from paraffin-embedded tumour tissue. 
BRAF V600E (GRCh37/hg19, chr7:g.140,453,136A>T; NM_004333, c.1799T>A; 
p.Val600Glu) mutation was detected by the analysis of single base primer extension 
products as part of a larger screen on genomic DNA using chip-based MALDI-TOF mass 
spectrometry (Sequenom Inc., San Diego, CA, USA). The assay was designed to enable 
detection of both reference and mutant alleles, and quantification of mutant allelic load. In 
addition to colorectal cancer samples, samples positive and negative for BRAF (V600E) 
(using Sanger sequencing and/or a diagnostic Sequenom panel at 5% sensitivity performed 
under NATA accredited conditions) were included as controls. 
Typer software (Version 4.0, Sequenom) was used to analyse the mass spectra (Figure 2). 
The software generated automated mutation calls using the default computational algorithms 
for SNP genotyping. Operator calling was performed blind (the operator being unaware of 
previous results) by optical inspection of the Typer Yield Call Cluster Plot, which compares 
the area under the curve of the extension product peak with that of the unextended primer 
peak (yield). Patient samples were called positive if they met the following criteria: negative 
control samples were clustered close to the origin, (2) plasmid standards were positioned 
away from the negative cluster, and (3) the positive control samples were confirmed to be 
positive (89). 
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Figure 2 – Typer software generated automated mutation calls 
!  
Statistical analyses were performed using the statistical software SAS 9.3 (SAS Institute 
Inc., Cary, NC, USA). The primary study endpoint was cancer specific survival. Non-cancer 
deaths were censored. Associations between BRAF, MSI and pathological factors were 
determined by logistic regression. Univariate analysis was performed using Kaplan-Meier 
survival curves and compared by a log rank test. Cox regression proportional hazard models 
were used for multivariate analysis with backward elimination. Cancer specific survival was 
compared among the groups MSI, BRAF and BRAF/MSI subgroups, and chemotherapy 
adjusted by various confounders. Four tumour categories were examined: MSS and BRAF-
ve (termed “traditional”), MSI and BRAF-ve (termed “presumed Lynch”), MSI and BRAF+ve 
(termed “sporadic MSI”) and MSS and BRAF+ve (termed “other BRAF”). The presence of a 
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BRAF (V600E) mutation confirms sporadic MSI rather than germline (52, 61). However, 
given we did not perform testing to identify the actual MMR mutation these germline MSI 
cases are labelled presumed Lynch. Backwards elimination was performed on each model 
to find a parsimonious model with all global P < 0.1 (except for the BRAF/MSI variate, which 
was kept in the model). 
Results 
Eight hundred and seventy-nine patients with stage III colon cancer were identified. Of 
these, 284 were excluded, 157 because insufficient tissue was available for molecular 
testing, 27 died in hospital perioperatively, five had metachronous cancers and four had a 
positive margin. This left 686 cases for analysis. Median follow-up was 52 months (0.4-329). 
BRAF mutation was identified in 15.7% (107/681) of tumours (some data for five patients 
were missing) and MSI observed in 13.8% (95/686). 
Table 1 shows clinicopathological differences between BRAF+ve and BRAF-ve cancers. 
BRAF+ve cancers were more likely to be proximal tumours (84%) and poorly differentiated 
(45%), and to have a mucinous component (71%), extramural vascular invasion (66.4%) and 
higher nodal stage (71%, i.e., N2 disease). 
Table 2 compares the BRAF/MSI subgroups. MSI cancers had a higher female 
preponderance regardless of BRAF status (63.8% presumed lynch and 73% sporadic MSI). 
Presumed lynch, other BRAF and sporadic MSI cancers had a higher rate of poor 
differentiation, were more likely to contain mucin and were more likely to be proximal 
compared to traditional cancers. The other BRAF group of cancers (MSS) had higher rate of 
extramural vascular invasion (70%) and perineural invasion (30.4%) compared to other 
groups. 
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Table 1 - Comparison of clinicopathologic characteristics of BRAF+ve and BRAF-ve 
patients
Subgroup Subcategory BRAF+ve BRAF-ve P
Median age 73.0 71.7 0.09
Number 107 574
Death 65 (73%) 246 (59.3%) 0.02
Chemotherapy 38 (36%) 233 (40.6%) 0.32
Gender
Male 45 (42%) 286 (49.8%)
0.14
Female 62 (57%) 288 (50.2%)
Proximal 
location
89 (84%) 275 (48.4%) <0.01
Poor 
differentiation
Poor 49 (46%) 93 (16.2%) <0.01
Type Mucinous 
component
76 (71%) 183 (31.9%) <0.01
Nodal stage
N1 31 (29%) 391 (68.1%)
<0.01
N2 76 (71%) 183 (31.9%)
T-stage
T1 + T2 3 (3%) 31 (05.4%)
0.34
T3 + T4 104 (97%) 543 (94.6%)
Extramural 71 (66%) 308 (54.2%) 0.02
Perineural 27 (26%) 102 (18.0%) 0.06
Obstruction 24 (23%) 102 (17.9%) 0.23
Perforation 10 (10%) 25 (4.4%) 0.03
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Table 2 - Comparison of clinicopathologic characteristics of the four MSI/BRAF subgroups
Subgroup Subcategory Traditional Presumed Lynch
Sporadic 
MSI Other BRAF P
Median age 71.7 72.0 75.4 71.6 0.01
Number 516 (75.8%) 58 (8.4%) 37 (5.4%) 70 (10.3%)
Chemotherapy 210 (40.4%) 23 (39.7%) 9 (24.3%) 29 (44.4%) 0.26
Gender
Male 251 (48.6%) 37 (63.8%) 27 (73.0%) 35 (50.0%)
0.007
Female 265 (51.4%) 21 (36.2%) 10 (27.1%) 35 (50.0%)
Proximal 
location 225




Poor 63 (12.2%) 30 (51.7%) 23 (62.2%) 26 (37.1%) <0.01
Type Mucinous 
component
145 (28.1%) 38 (65.5%) 28 (75.7%) 48 (68.6%) <0.01
Nodal stage
N1 381 (73.8%) 41 (70.7%) 22 (59.9%) 39 (55.7%)
<0.01
N2 135 (26.2%) 17 (29.3%) 15 (40.5%) 31 (44.3%)
T-stage
T1 + T2 30 (5.8%) 1 (1.7%) 0 (0%) 3 (4.3%)
0.36
T3 + T4 486 (94.2%) 57 (98.0%) 37 (100%) 67 (95.7%)
Extramural 280 (54.9%) 28 (48.3%) 22 (59.5%) 49 (70.0%)
0.06
Perineural 96 (18.9%) 6 (10.3%) 6 (16.7%) 21 (30.4%) 0.03
Obstruction 94 (18.4%) 8 (13.8%) 5 (13.9%) 19 (27.5%) 0.16
Perforation 25 (4.9%) 0 (0%) 4 (11.4%) 6 (8.6%) 0.05
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Univariate analysis indicated a statistically significant difference in cancer specific survival 
between BRAF+ve vs BRAF-ve cancers, with BRAF+ve cancers having shorter survival than 
BRAF-ve cancers (Figure 3). 
Figure 3 – Kaplan-Meier curve comparing cancer specific survival between BRAF+ve and 
BRAF-ve cancers 
There was no difference in cancer specific survival between MSI and MSS cases in this 
cohort of node positive patients (Figure 4). 
At 5 years Survival Failure Number fail Number left
BRAF+ve 0.41 0.58 60 36
BRAF-ve 0.61 0.38 199 276
 35
P < 0.01
Figure 4 - Kaplan-Meier curve comparing cancer specific survival between MSI and MSS 
cancers 
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When the four subgroups are examined (Figure 5) there was a statistically significant 
difference in cancer specific survival across the groups. Presumed Lynch and traditional 
cancers had a similarly good survival compared to the BRAF cancers, both sporadic MSI 
and other BRAF, which were similar. 
At 5 years Survival Failure Number fail Number left
MSI 0.53 0.46 41 35
MSS 0.59 0.40 218 280
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P = 0.39
Figure 5 – Kaplan-Meier curve comparing cancer specific survival between four MSI/BRAF 
subgroups 
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On the multivariate model (Table 3, adjusting for chemotherapy, age, T-stage, nodal stage, 
obstruction, perforation, extramural and perineural invasion), neither BRAF nor MSI status 
was prognostically significant. There was a trend towards poorer outcomes in BRAF+ve (HR 
1.27, 95% CI 0.89-1.80, P = 0.18) and MSI (HR 1.17, 95% CI 0.75-1.83, P = 0.48) cancers.	
At 5 years Survival Failure Number fail Number left
Lynch 0.61 0.38 21 28
Traditional 0.62 0.37 178 253
Sporadic MSI 0.42 0.57 20 12













Adjusted analysis on the four subgroups showed that none were independently 
prognostically significant despite the univariate findings (Table 4). Notably the BRAF+ve 
MSS (other BRAF) cancers did not have a poorer outcome after adjustment for other factors. 
In an adjusted model comparing other BRAF to all other tumours as a single group, there 
was no significant difference in cancer specific survival (HR 0.78, 95% 0.55-1.10, p = 0.15). 
Table 3 - Cox proportional hazard model, adjusting for clinicopathological factors, BRAF 
and MSI
Variate HR 95% CI P
BRAF+ve 1.27 0.89 - 1.80 0.18
MSI 1.17 0.75 - 1.83 0.48
Chemotherapy 0.66 0.49 - 0.88 <0.01
N1 0.50 0.39 - 0.66 <0.01
T1 + T2 0.39 0.14 - 1.07 0.06
Extramural 1.67 1.26 - 2.21 <0.01
Perineural 1.67 1.22 - 2.29 <0.01
Obstruction 1.43 1.06 - 1.91 0.01
Perforation 2.20 1.45 - 3.34 <0.01
Backward stepwise elimination, excluding non-significant variates >0.1, i.e., no gender, grade, 
location and type.
Table 4 - Cox proportional hazard model, adjusting for clinicopathological factors and four 
subgroups
Multivariate analysis of four subgroups
Variate HR 95% CI P
Non-Lynch vs Lynch 1.02 0.65 - 1.61 0.90
Non-sporadic MSI vs 
sporadic MSI 0.94 0.58 - 1.53 0.81
Non-other BRAF vs 
other BRAF 0.78 0.55 - 1.10 0.15
Non-traditional vs 
traditional 1.14 0.86 - 1.51 0.34
Excluding non-significant variates >0.1 
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Discussion 
This was a retrospective cohort study investigating the impact of BRAF mutation (with and 
without MSI) on survival. BRAF mutation was associated with poorer survival when 
compared to BRAF wild type on univariate analysis. However, on multivariate analysis, there 
was no statistically significant relationship between BRAF and survival regardless of MSI 
status in this group of node positive colon cancer patients. 
The BRAF V600E mutation occurs at a high frequency in serrated cancer and can help 
distinguish inherited from sporadic cancers (52, 61). Similar to previous reports (59), we 
found that BRAF mutation was associated with some adverse features, including poor 
differentiation, presence of mucin, extramural invasion and high nodal stage, suggesting 
BRAF mutated cancer will do poorly. However, when multivariate analysis was conducted on 
stage III colon cancer patients only, we found that BRAF mutation was not an independent 
prognostic biomarker. Published data have been conflicting (50, 60, 64). A meta-analysis of 
26 colorectal cancer studies (published in 2013) suggested that BRAF mutation is 
independently associated with poor survival (59). However, most of the studies analysed 
were heterogenous, with not all studies adjusting for clinicopathological variables and 
chemotherapy, and many including cancers at all  stages as well as rectal cancer cases. In 
our study, MSI status was not found to be prognostically significant in stage III colon cancer, 
on adjusted analysis. It may be that the inclusion of stage III cases only influenced the 
results, suggesting that the favourable impact on survival of MSI reported in previous studies 
might be in early-stage disease only (55, 56). 
We also investigated whether the combination of BRAF mutation and MSI status, might 
provide useful prognostic information beyond the evaluation of either factor alone. 
Consistent with previous studies (47, 83, 90), adjusted analysis of the other BRAF group 
(BRAF+ve/MSS) with poor histological features revealed non-significant trend towards a 
poor outcome (Table 4). The inability in our study to reach statistical significance, despite 
such a big difference in survival rates, may reflect the low number of patients with this 
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tumour phenotype (BRAF+ve/MSS). We did not observe the better outcome that some 
others have shown in Lynch patents (55, 56). 
The current study has some limitations. The incidence of BRAF mutation in our study was 
similar to that reported in literature (91), but we found a slightly higher percentage of MSI 
and presumed Lynch cases (8.4%), which likely reflects more comprehensive testing. Data 
from a large RCT have shown that addition of oxaliplatin to adjuvant 5-FU may further 
improve prognosis of MSI CRC (92). However, we only included patients who received 5-
FU-based regimens to allow for appropriate comparisons. Retrospective data collected from 
33 years may contain biases. To overcome this, we included a large number of patients, 
adjusted for pathological variables and chemotherapy and limited the study to stage III colon 
cancers. In addition, to ensure accuracy of data in our study, pathology was reassessed 
from slides the earlier cases to meet current reporting protocols. Clinical information was 
also extensively cross checked from different sources. 
Conclusions 
BRAF mutation was associated with poorer survival when compared to BRAF wild type on 
univariate analysis of stage III colorectal cancer. However, on multivariate adjusted analysis 
there was no statistically significant relationship between BRAF and survival in stage III 
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Purpose: The predictive role of biomarkers in colon cancer is still being defined. The aim of 
this study is to determine the interaction between BRAF mutation and microsatellite 
instability (MSI) status in determining survival benefit after adjuvant 5-FU based 
chemotherapy in stage III colon cancer. 
Methods: We performed a retrospective cohort study including all curatively resected stage 
III colon cancer cases over a 33-year period. A clinicopathologic database was collated 
(adjuvant chemotherapy, age, gender, obstruction, perforation, tumour location, grade, 
mucin, nodal stage, extramural vascular and perineural invasion). BRAF (V600E) mutation 
testing was performed and MSI status established by immunohistochemistry for mismatch 
repair proteins and molecular testing for National Cancer Institute panel markers. Patients 
were categorised into four groups for comparison: MSS and BRAF-ve (termed “traditional”), 
MSI and BRAF-ve (termed “presumed Lynch”), MSI and BRAF+ve (termed “sporadic MSI”) 
and MSS and BRAF+ve (termed “other BRAF”). The primary endpoint was cancer specific 
survival. Interaction testing was conducted to determine whether there were different 
responses to chemotherapy between groups. 
Results: A total of 686 unselected cases met inclusion criteria and had tissue available, of 
which 15.7% had BRAF mutation (BRAF+ve) and 13.8% had MSI. Thirty-nine percent 
received chemotherapy. Overall, adjuvant chemotherapy produced a cancer specific survival 
benefit (HR 0.66, 95% CI 0.49-0.88, P < 0.01). On adjusted analysis, neither BRAF nor MSI 
status were individually predictive of survival benefit. On adjusted analysis specifically of the 
chemotherapy effect in each subgroup, only patients in the presumed Lynch (HR 0.260, 95% 
CI 0.09-0.80, P < 0.01) and other BRAF groups (HR 0.45, 95% CI 0.23-0.87, P < 0.01) had a 
significant survival benefit from chemotherapy. On interaction testing of subgroups, adjusting 
for all the clinicopathological parameters, only patients in the presumed Lynch group (HR 
0.277, 95% CI 0.10-0.75, P < 0.01) gained a differentially greater benefit from chemotherapy 
than other groups. 
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Conclusions: In this historical cohort, MSI testing is predictive of response to adjuvant 
chemotherapy in stage III colon cancer, but only when results are interpreted in combination 
with BRAF. This supports the role of routine testing for these biomarkers. 
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Introduction 
5-Fluorouracil (5-FU) based chemotherapy regimens are commonly used in the adjuvant 
treatment of stage III colon cancer and are known to moderately reduce the risk of 
recurrence and death in this subset of patients (8-10%% improvement in overall survival) 
(68, 93). Given the potential toxicity, cost and inconvenience associated with chemotherapy 
treatment, the use of predictive biomarkers to help individualise adjuvant treatment is 
appealing. 
Studies looking at microsatellite instability (MSI) as a predictive biomarker for chemotherapy 
response are inconsistent. While many studies have suggested that MSI tumours do not 
respond to 5-FU based chemotherapy (42, 80), and that chemotherapy may even have a 
detrimental effect on survival, others have found that MSI tumours gain similar survival 
benefit from adjuvant chemotherapy as non-MSI cancers (57, 72, 81). This has led to 
variation in the recommended management due to difference in interpretation of the 
published data. 
The role of BRAF V600E mutations is reasonably well established in metastatic colorectal 
disease. This mutation is responsible for conferring anti-EGFR (epithelial growth factor 
receptor) antibody resistance and is considered to be partly responsible for the 12-15% of 
patients who do not respond to anti-EGFR treatment in the palliative setting (94). The 
National Comprehensive Cancer Network (95) guidelines now recommend BRAF mutation 
testing in all patients with metastatic colorectal disease (95). In the adjuvant setting, BRAF 
status has not generally been considered to be a predictive biomarker, however, research in 
this area has been relatively limited (72, 73, 83). 
The aim of this study was to determine the interaction between BRAF mutation and MSI 




This was a retrospective cohort study. All identifiable patients treated for colonic 
adenocarcinoma over a 33-year period within the Central and Northern Adelaide Local 
Health Network in Australia were screened for inclusion. Adult patients who underwent 
surgery with curative intent were included. Patients were excluded if death occurred 
perioperatively, if the surgical margin was positive for tumour (R1 or R2 resection), or if they 
had metachronous colorectal cancer within 5 years. Synchronous cancers were included. 
Patient data were derived, linked and collated from regional and national cancer registries 
and pathology databases. Individual pathology reports were reviewed, and pathology 
reassessed from slides on the earlier cases to meet current standardised reporting 
protocols. 
A clinicopathologic database was created including data on patient age, gender and whether 
they received adjuvant 5-FU chemotherapy. Patients receiving other chemotherapy agents 
were excluded. Tumour characteristics, including obstruction (defined as proximal dilatation 
on the pathology report), perforation (defined as occurring through the tumour on the 
pathology report) and tumour location, were recorded. Proximal cancers were defined as 
cancers from the caecum to the splenic flexure inclusively and distal cancers defined as 
tumours distal to the splenic flexure. Histologic features, including grade (well and 
moderately differentiated tumours were grouped together, and poorly differentiated tumours 
recorded separately), mucinous component (positive if mucin present on histology), T-stage 
(T1 and T2 grouped together, and similarly T3 and T4), nodal stage (N1 vs N2), extramural 
vascular and perineural invasion, were recorded. Death data were sourced from the South 
Australian State Cancer Registry, hospital cancer registry, patient case notes and by 
checking patients’ final clinic visit. Hospital and state cancer registries are regularly updated 
with information from national databases to capture interstate deaths. Patient case notes 
were reviewed if required to replace missing data. 
MSI status was established on formalin fixed paraffin embedded (FFPE) archived specimens 
from 1980 to 2002 by determining instability in mononucleotide sequences BAT40 and 
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BAT26, the latter being highly specific for MSI high (96). The complete National Cancer 
Institute (NCI) panel was run on equivocal cases with MSI defined by instability in two or 
more markers. From 2002 onwards, MSI status has routinely been established on patients 
through IHC expression of DNA mismatch repair (MMR) proteins and by molecular testing 
for the full NCI panel of markers (BAT25, BAT26, BAT40, D2S123, D10S197, D17S579, 
D18S34, D5S346 and D17S250). Tumours showing instability at two or more loci were 
defined as microsatellite unstable (MSI). Tumours showing no abnormal loci or instability at 
one locus were classified as microsatellite stable (MSS). 
Mutation testing was performed on DNA isolated from paraffin-embedded tumour tissue. 
BRAF V600E (GRCh37/hg19, chr7:g.140,453,136A>T; NM_004333, c.1799T>A; 
p.Val600Glu) mutation was detected by the analysis of single base primer extension 
products as part of a larger screen on genomic DNA using chip-based MALDI-TOF mass 
spectrometry (Sequenom Inc., San Diego, CA, USA). The assay was designed to enable 
detection of both reference and mutant alleles, and quantification of mutant allelic load. In 
addition to colorectal cancer samples, samples positive and negative for BRAF (V600E) 
(using Sanger sequencing and/or a diagnostic Sequenom panel at 5% sensitivity performed 
under NATA accredited conditions) were included as controls. 
Typer software (Version 4.0, Sequenom) was used to analyse the mass spectra (Figure 6). 
The software generated automated mutation calls using the default computational algorithms 
for SNP genotyping. Operator calling was also performed blind (the operator being unaware 
of previous results) by optical inspection of the Typer Yield Call Cluster Plot, which compares 
the area under the curve of the extension product peak with that of the unextended primer 
peak (yield). Patient samples were called positive if they met the following criteria: negative 
control samples were clustered close to the origin, (2) plasmid standards were positioned 
away from the negative cluster, and (3) the positive control samples were confirmed to be 
positive (89). 
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Figure 6 – Typer software generated automated mutation calls 
!  
Statistical analyses were performed using the statistical software SAS 9.3 (SAS Institute 
Inc., Cary, NC, USA). Four patient categories were examined: MSS and BRAF-ve (termed 
“traditional”), MSI and BRAF-ve (termed “presumed Lynch”), MSI and BRAF+ve (termed 
“sporadic MSI”) and MSS and BRAF+ve (termed “other BRAF”). The primary study endpoint 
was cancer specific survival (non-cancer deaths were censored). This was compared 
between the groups, and associations between BRAF, MSI and pathological factors were 
determined by logistic regression. Univariate survival analysis was performed using Kaplan-
Meier survival curves and compared using a log rank test. 
Adjusted analysis was performed using Multivariate Cox Proportional Hazard Models with 
backward elimination adjusting for the identified confounders. Subgroup analysis was 
performed on each of the four MSI/BRAF combination groups determining the hazard ratio 
of chemotherapy effect in that subgroup. From the adjusted model of the whole group, 
interaction testing was performed to determine if one of the four MSI/BRAF subgroups had a 
greater effect from chemotherapy than the others by creating an eight-variate model with 
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each subgroup with or without chemotherapy, with P < 0.10 (except for the BRAF/MSI 
variate, which was retained in the model). 
Appropriate ethics approval was obtained from the Royal Adelaide Hospital Human 
Research Ethics Committees (approval number 140108). 
Results 
Eight hundred and seventy-nine patients with stage III colon cancer were identified. Of 
these, 284 were excluded, 157 because insufficient tissue was available for molecular 
testing, 27 died in hospital perioperatively, five had metachronous cancers and four had a 
positive margin. This left 686 cases for analysis. Median follow-up was  52 months (0.4-329). 
BRAF mutation was identified in 15.7% (107/681) of tumours (five patients had missing data) 
and MSI observed in 13.8% (95/686). Of the 681 patients that had complete molecular 
profile, 75.8% (516/681) were in the traditional group, 8.5% (58/681) were presumed Lynch, 
5.4% (37/681) were sporadic MSI and 10.3% (70/681) were other BRAF. Two hundred and 
seventy-one patients received postoperative adjuvant chemotherapy and 415 patients did 
not, partly due to inclusion of patients before the routine use of adjuvant chemotherapy (n = 
140) circa 1991. 
Table 5 shows clinicopathological differences between tumours in patients who received 
adjuvant chemotherapy versus those who did not. Patients who received chemotherapy 
were younger, more likely to be male, had a higher rate of extramural and perineural 
invasion, but had improved cancer specific survival. The two groups were otherwise well 
matched, particularly with regards to BRAF and MSI status. There was no significant 
difference in the rates of adjuvant chemotherapy use in any of the four subgroups (Table 5). 
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Univariate analysis of cancer specific survival indicated statistically significant overall 
differences between the four patient groups (Figure 7). 
Table 5 - Comparison of clinicopathologic differences between patients who received 
chemotherapy and patients who did not
Chemo No chemo P
Age at surgery (mean±SD) 65.3±11.0 73.8±11.9 <0.01
Male 154 (57%) 179 (43%) <0.01
Female 117 (43%) 236 (57%)
Cancer-related death 164 (61%) 343 (83%) <0.01
Differentiation - well/moderate 212 (78%) 331 (80%)       
      0.63 
      0.59 
Differentiation - poor 59 (22%) 84 (20%)
Mucinous component 99 (37%) 160 (39%)                                             
Obstruction 43 (16%) 83 (20%) 0.18
Perforation 15 (6%) 20 (5%) 0.68
Extramural 163 (61%) 216 (52%) 0.03
Perineural 61 (23%) 68 (17%) 0.04
MSI 32 (12%) 63 (15%) 0.21
BRAF 38 (14%) 69 (17%) 0.32
Traditional 210 (77%) 306 (75%)
0.26
Sporadic MSI 9 (3.3%) 28 (6.8%)
Lynch 23 (8.4%) 35 (8.5%)
Other BRAF 29 (11%) 41 (10%)
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Figure 7 – Kaplan-Meier curve comparing cancer specific survival between four MSI/
BRAF subgroups 
!  
In patients who were BRAF+ve (combining sporadic MSI and other BRAF groups) there was 
no apparent survival benefit from adjuvant chemotherapy (Figure 8), whereas, in patients 
who exhibited MSI (including both presumed Lynch and sporadic MSI groups), there was a 
clear survival benefit (Figure 9). 
At 5 years Survival Failure Number fail Number left
Lynch 0.61 0.38 21 28
Traditional 0.62 0.37 178 253
Sporadic MSI 0.42 0.57 20 12













Figure 8 – Kaplan-Meier curve comparing cancer specific survival in BRAF+ve 
group with or without chemotherapy 
!  
At 5 years Survival Failure Number fail Number left
BRAF+ve Chemo 0.48 0.51 19 16
BRAF+ve No chemo 0.37 0.63 41 20
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P = 0.12
Figure 9 - Kaplan-Meier curve comparing cancer specific survival in MSI group with or 
without chemotherapy 
!  
When the four distinct patient groups were examined on univariate analysis, a survival 
benefit for chemotherapy could only be demonstrated in the presumed Lynch group (MSI/
BRAF-ve) (Figure 10). Interestingly, the benefit in traditional cancer, when examined in 
isolation without adjustment, failed to reach significance (p = 0.09, Figure 11). 
At 5 years Survival Failure Number fail Number left
MSI Chemo 0.73 0.26 8 20
MSI No chemo 0.43 0.56 33 16
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P < 0.01
Figure 10 – Kaplan-Meier curve comparing cancer specific survival benefit from 
chemotherapy in MSI subgroups (sporadic MSI and presumed Lynch) 
!  
At 5 years 
(Sporadic MSI) Survival Failure Number fail Number left
Chemo 0.53 0.46 4 4
No chemo 0.39 0.60 16 18
At 5 years 
(Presumed Lynch)
Survival Failure Number fail Number left
Chemo 0.82 0.17 4 17
No Chemo 0.47 0.52 17 13
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Figure 11 - Kaplan-Meier curve comparing cancer specific survival benefit from 
chemotherapy in other BRAF and traditional subgroups 
!  
At 5 years  (Other 
BRAF)
Survival Failure Number fail Number left
Chemo 0.47 0.52 15 12
No chemo 0.35 0.64 25 12
At 5 years 
(Traditional)
Survival Failure Number fail Number left
Chemo 0.65 0.34 68 117
No chemo 0.59 0.40 110 136
 55
Other	BRAF Chemo vs no chemo (MSS 
and BRAF+ve)
Tradi<onal	Chemo vs no chemo (MSS 
and BRAF-ve)
On analysis adjusting for other prognostic factors in each of the four subgroups determining 
the chemotherapy effect on cancer specific survival, the presumed Lynch and other BRAF 
(MSS/BRAF+ve) groups reached significance (Table 6). However, interestingly, interaction 
testing reached significance for the presumed Lynch (MSI/BRAF-ve) group suggesting the 
chemotherapy benefit was highest in this group (Table 7). 
Table 6 - Adjusted analysis of the chemotherapy effect on cancer specific survival in each 
subgroup
Multivariate Hazard Model: Chemotherapy effect in each subgroup
Group  N HR 95% CI P
Traditional 516 (75.8%) 0.76 0.57 – 1.03 0.08
Sporadic MSI 37 (5.4%) 0.64 0.23 – 1.99 0.44
Other BRAF 70 (10.3%) 0.45 0.23 – 0.87 0.01
Presumed Lynch 58 (8.5%) 0.26 0.08 – 0.79 0.01
Table 7 - Interaction testing of the chemotherapy effect in each subgroup
Multivariate Hazard Model: Interaction testing of the chemotherapy effect in each subgroup
Group  N HR 95% CI P Overall P
Traditional 516 (75.8%) 0.80 0.62 - 1.05 0.11
<0.01
Sporadic MSI 37 (5.4%) 0.54 0.18 – 1.61 0.27
Other BRAF 70 (10.3%) 0.68 0.37 – 1.24 0.21
Presumed Lynch 58 (8.5%) 0.27 0.10 – 0.75 0.01
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Discussion 
Our findings suggest that MSI/BRAF subtyping has a predictive role in the clinical setting of 
curatively resected stage III colorectal cancer. While there was an overall benefit from 
adjuvant chemotherapy, the presumed Lynch group gained differentially greater benefit from 
chemotherapy than the other groups when taking into account clinicopathologic parameters. 
Our study differs from published studies as we determined the predictive role of MSI and 
BRAF in combination, whereas previous research focused on MSI and BRAF separately. 
This may explain some of the conflicting results in the literature. 
The role of BRAF V600E mutations as a predictive biomarker in the adjuvant setting is 
unclear, with very few studies looking at this specifically (72, 73, 83). Hutchins et al., 
analysing data from the QUASAR trial, studied BRAF mutation in predicting recurrence and 
benefit from chemotherapy in stage II colon cancer and found the BRAF mutation not to be 
predictive of chemotherapy benefit (72). However, this study had limited statistical power to 
demonstrate any interactions between the molecular markers and the efficacy of 
chemotherapy due to few recurrences in early stage disease (72). Similarly, the MRC 
FOCUS trial found no evidence of impact on overall survival, however, the relative 
infrequency of BRAF mutation in the studied patient cohort made this study underpowered to 
detect or exclude any BRAF-specific effect (73). Interestingly, Ogino et al. found a non-
significant trend towards better survival in stage III colorectal cancer patients with BRAF 
V600E mutation on adjusted analysis (83). 
There is considerable literature on the predictive role of MSI, but the findings are conflicting. 
Evidence from earlier in vitro studies has indicated that inactivation of the MMR system can 
result in resistance to 5-FU treatment (74-76). Several early retrospective studies suggested 
greater chemotherapy benefit in MSI-H cases (40, 41, 77), but may have only served to 
highlight the overall better prognosis seen in MSI-H cases (74, 75, 89). In contrast, to prior 
studies, in 2003, Ribic et al. retrospectively analysed data from five RCTs and found a trend 
towards MSI showing less benefit from 5-FU based chemotherapy (42). Subsequently in 
2010, Sargent et al. pooled data from the Ribic et al. study with the addition of 457 cases 
 57
and reported similar results in stage III cancer (80).  However, more recent evidence, in 
contrast to Ribic and Sargent et.al study, found MSI status  does not affect chemotherapy 
responsiveness (57, 72, 81). Interestingly, when Sinicrope et al. re-analysed data from 
previous RCT’s with patients from Ribic and Sargent studies, they found MSI status to be 
predictive of chemotherapy benefit, however, the effect was limited to germline cases 
(presumed Lynch) (82), a finding that is consistent with our current results. Unlike our study, 
Sinicrope et al. did not use BRAF V600E (a more reliable way to differentiate sporadic from 
germline MSI cancers) in all patients to subclassify MSI cancers, instead in some patients 
assuming Lynch syndrome if there was MLH1 loss in patients under 55 years at diagnosis. 
The incidence of BRAF mutation in our study was similar to that reported in the literature, but 
we found a slightly higher percentage of MSI and presumed Lynch cases (91). The higher 
rate of presumed Lynch cases (8.4%) likely reflects our stringent testing protocols, and the 
recent adoption of routine testing. Nevertheless, our study has some limitations. Non-
randomised data have potential bias, but to overcome this we included cases from an era 
prior to routine use of chemotherapy in stage III colon cancer (circa 1990). Patients in the 
chemotherapy group were 8 years younger than those in the non-chemotherapy group, 
indicating that age may have influenced who was selected for adjuvant treatment, however, 
to overcome this we comprehensively adjusted for all clinicopathological factors and age. 
The strengths of the study include the large number of patients, the inclusion of a 
homogeneous group of stage III colon cancers (i.e. no rectal cancers were included), and 
adjustment for pathological variables and chemotherapy. To ensure accuracy of data, we re-
examined all pathology reports and pathology was reassessed from slides on the earlier 
cases to meet current reporting protocols. Also, clinical information, in particular mortality, 
was extensively cross checked from multiple sources. 
While we did not have mutation testing to confirm Lynch syndrome, we tested for BRAF 
V600E mutation in all cases (unlike previous studies) and used this as a marker to identify 
presumed Lynch patients. 
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Conclusions 
In conclusion, our study emphasises the importance of testing for BRAF mutation and MSI in 
stage III colon cancer. Doing so may help individualise adjuvant treatment, particularly for 
MSI cancers, who may not have been considered for 5-FU chemotherapy based on older 






In this study, on initial analysis, it appeared that patients with cancer with BRAF mutation 
had a poorer survival. However, after adjusting for clinicopathologic parameters, BRAF 
mutation was not found to be associated with a poorer prognosis, even when considered in 
combination with MSI. Interestingly, MSI cases were found to benefit from adjuvant 
chemotherapy, however, it was the germline MSI cases that had a significantly greater 
benefit from chemotherapy than the other groups. 
By using this historical cohort, we have attempted to overcome some of the shortcomings of 
earlier studies. Those studies included rectal cancers, which are known to be distinct from 
colon cancer, particularly at stage III, and patients with these cancers often receive 
neoadjuvant radiation/chemotherapy treatment. Also, the patterns of recurrence and survival 
are different for colon and rectal cancers. Therefore, the exclusion of rectal cancer from our 
study improves the reliability of the conclusions. Unlike some earlier studies, we only 
included stage III colon cancers, which allowed us to form conclusions specific to that stage  
The greatest strength of this study is its large sample size, carefully-validated dataset, and 
the inclusions of patients over a 33-year period. We comprehensively adjusted for prognostic 
clinicopathological parameters and looked for compounding effect of chemotherapy for 
individual and combined biomarkers. 
Future Research 
The trends identified in our study need further evaluation. CRC cancer tumorigenesis is 
particularly heterogeneous, and has proven difficult to understand and fully delineate, 
particularly all the molecular alterations. However, as knowledge of the molecular landscape 
of colorectal tumorigenesis advances, new molecular biomarkers with potential prognostic 
and predictive value will be discovered. These biomarkers may lead to improved tumour 
molecular classification, and potentially help individualise treatment of colon cancer patients.  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